Hello, everyone, and how are you today? We are doing just fine, thank you, as we dig in to enjoy the nail-biting election underway on this side of the pond. The stakes are high. The drama is intense. The tension is palpable. Please forgive us for sounding like an old-time radio announcer, but this should be an interesting day. Nonetheless, there is work to be done. So feel free to join us as we fire up the coffee kettle and quaff some needed cups of stimulation. Meanwhile, here are a few items of interest to help you along. Hope today goes well, whatever the outcome, and do keep in touch …

Takeda Pharmaceutical (TKPPY) chief executive Christophe Weber maintains he is confident of securing investor backing for the $62 billion acquisition of Shire (SHPG), despite some shareholder fears about the resulting debt burden, The Japan Times writes. Takeda (TAK) received a $30.9 billion bridge loan to help finance the deal, but some investors are concerned as to how well it will cope with debt repayments. A group including members of Takeda’s founding family oppose the deal and plan to sue Takeda in order to obtain details of the board talks leading up to the offer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy